{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"21.6","value":"7.79"},{"groupId":"OG001","spread":"46.3","value":"40.9"},{"groupId":"OG002","spread":"35.8","value":"95.9"},{"comment":"Only 1 participant analyzed","groupId":"OG003","spread":"NA","value":"314"},{"groupId":"OG004","spread":"15.5","value":"305"},{"groupId":"OG005","spread":"12.4","value":"404"}]}],"title":"C1D1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"24.1","value":"9.50"},{"groupId":"OG001","spread":"23.6","value":"48.6"},{"groupId":"OG002","spread":"47.5","value":"153"},{"comment":"Only 1 participant analyzed","groupId":"OG003","spread":"NA","value":"394"},{"groupId":"OG004","spread":"38.9","value":"541"},{"groupId":"OG005","spread":"24.7","value":"966"}]}],"title":"C2D8"}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"4"},{"groupId":"OG005","value":"3"}],"units":"Participants"}],"dispersionType":"Standard Deviation","groups":[{"description":"Participants in Arm A received 60 mg dose of RO7297089 as a flat dose at each scheduled study drug administration visit","id":"OG000","title":"Dose Escalation Cohort 1: RO7297089"},{"description":"Participants in Arm A received 180 mg dose of RO7297089 as a flat dose at each scheduled study drug administration visit","id":"OG001","title":"Dose Escalation Cohort 2: RO7297089"},{"description":"Participants in Arm A received 360 mg dose of RO7297089 as a flat dose at each scheduled study drug administration visit","id":"OG002","title":"Dose Escalation Cohort 3: RO7297089"},{"description":"Participants in Arm A received 1080 mg dose of RO7297089 as a flat dose at each scheduled study drug administration visit","id":"OG003","title":"Dose Escalation Cohort 4: RO7297089"},{"description":"Participants in Arm B received the 1080 mg dose of RO7297089 as a split dose divided over two days (Days 1 and 2). The full target dose wasadministered at subsequent study drug administration visits.","id":"OG004","title":"Dose Escalation Backfill Cohort 4: RO7297089"},{"description":"Participants in Arm B received the 1850 mg dose of RO7297089 as a split dose divided over two days (Days 1 and 2). The full target dose was administered at subsequent study drug administration visits.","id":"OG005","title":"Dose Escalation Cohort 5: RO7297089"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"Only those participants who received full dose were included in the results summary","reportingStatus":"POSTED","timeFrame":"Cycle 1 Day 1, Cycle 2 Day 8","title":"Maximum Concentration Observed (Cmax) of RO7297089","type":"SECONDARY","unitOfMeasure":"ug/mL"}